AU2017379796B2 - Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof - Google Patents

Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof Download PDF

Info

Publication number
AU2017379796B2
AU2017379796B2 AU2017379796A AU2017379796A AU2017379796B2 AU 2017379796 B2 AU2017379796 B2 AU 2017379796B2 AU 2017379796 A AU2017379796 A AU 2017379796A AU 2017379796 A AU2017379796 A AU 2017379796A AU 2017379796 B2 AU2017379796 B2 AU 2017379796B2
Authority
AU
Australia
Prior art keywords
mmol
amino
pyrimidin
ethyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2017379796A
Other languages
English (en)
Other versions
AU2017379796A1 (en
Inventor
Jianwei Che
Tinghu Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Isocure Biosciences Inc
Original Assignee
Isocure Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isocure Biosciences Inc filed Critical Isocure Biosciences Inc
Publication of AU2017379796A1 publication Critical patent/AU2017379796A1/en
Application granted granted Critical
Publication of AU2017379796B2 publication Critical patent/AU2017379796B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AU2017379796A 2016-12-19 2017-12-18 Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof Ceased AU2017379796B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662436328P 2016-12-19 2016-12-19
US62/436,328 2016-12-19
US201762536367P 2017-07-24 2017-07-24
US62/536,367 2017-07-24
PCT/US2017/067050 WO2018118793A1 (en) 2016-12-19 2017-12-18 Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof

Publications (2)

Publication Number Publication Date
AU2017379796A1 AU2017379796A1 (en) 2019-07-04
AU2017379796B2 true AU2017379796B2 (en) 2021-10-21

Family

ID=62627122

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017379796A Ceased AU2017379796B2 (en) 2016-12-19 2017-12-18 Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof

Country Status (8)

Country Link
US (2) US11149032B2 (OSRAM)
EP (1) EP3555079A4 (OSRAM)
JP (1) JP2020502116A (OSRAM)
KR (1) KR20190092476A (OSRAM)
CN (1) CN110291085B (OSRAM)
AU (1) AU2017379796B2 (OSRAM)
CA (1) CA3047136A1 (OSRAM)
WO (1) WO2018118793A1 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10696665B2 (en) * 2016-06-06 2020-06-30 Eli Lilly And Company Mutant IDH1 inhibitors
WO2019213403A1 (en) 2018-05-02 2019-11-07 Kinnate Biopharma Inc. Inhibitors of cyclin-dependent kinases
KR20210040368A (ko) * 2018-06-29 2021-04-13 킨네이트 바이오파마 인크. 사이클린 의존성 키나제의 억제제
CN111825666B (zh) * 2019-04-23 2024-03-08 上海仕谱生物科技有限公司 二聚或多聚体形式的突变型idh抑制剂
US20230405135A1 (en) * 2020-09-14 2023-12-21 Totus Medicines Inc. Therapeutic conjugates
CN120554346A (zh) * 2024-02-28 2025-08-29 中国科学院上海药物研究所 一类噁唑酮取代的嘧啶胺化合物及其制备方法、药物组合物和用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013046136A1 (en) * 2011-09-27 2013-04-04 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
WO2016044781A1 (en) * 2014-09-19 2016-03-24 Forma Therapeutics, Inc. Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors
WO2017140758A1 (en) * 2016-02-19 2017-08-24 Debiopharm International S.A. Derivatives of 2-amino-4-(2-oxazolidinon-3-yl)-pyrimidine fused with a five-membered heteroaromatic ring in 5,6-position which are useful for the treatment of various cancers
WO2017213910A1 (en) * 2016-06-06 2017-12-14 Eli Lilly And Company Mutant idh1 inhibitors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2400447C (en) * 2000-02-17 2008-04-22 Amgen Inc. Kinase inhibitors
AR064571A1 (es) * 2006-12-28 2009-04-08 Basf Ag Pirimidinas sustituidas en posicion 2 por heterociclos nitrogenados, medicamentos y composiciones farmaceuticas que las contienen y usos de las mismas en el tratamiento del cancer.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013046136A1 (en) * 2011-09-27 2013-04-04 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
WO2016044781A1 (en) * 2014-09-19 2016-03-24 Forma Therapeutics, Inc. Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors
WO2017140758A1 (en) * 2016-02-19 2017-08-24 Debiopharm International S.A. Derivatives of 2-amino-4-(2-oxazolidinon-3-yl)-pyrimidine fused with a five-membered heteroaromatic ring in 5,6-position which are useful for the treatment of various cancers
WO2017213910A1 (en) * 2016-06-06 2017-12-14 Eli Lilly And Company Mutant idh1 inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JULIAN R. LEVELL ET AL, ACS MEDICINAL CHEMISTRY LETTERS, US, (2016-12-16), vol. 8, no. 2, doi:10.1021/acsmedchemlett.6b00334, ISSN 1948-5875, pages 151 - 156 *

Also Published As

Publication number Publication date
EP3555079A1 (en) 2019-10-23
KR20190092476A (ko) 2019-08-07
CN110291085B (zh) 2023-01-24
AU2017379796A1 (en) 2019-07-04
WO2018118793A1 (en) 2018-06-28
CN110291085A (zh) 2019-09-27
US20210403460A1 (en) 2021-12-30
US20200071309A1 (en) 2020-03-05
EP3555079A4 (en) 2020-08-19
JP2020502116A (ja) 2020-01-23
US11149032B2 (en) 2021-10-19
CA3047136A1 (en) 2018-06-28

Similar Documents

Publication Publication Date Title
AU2017379796B2 (en) Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof
AU2024201128B2 (en) Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
CN113135910A (zh) 嘧啶-4(3h)-酮类杂环化合物、其制备方法及其在医药学上的应用
JP2020525525A (ja) Ｒｈｏ−関連プロテインキナーゼ阻害剤、ｒｈｏ−関連プロテインキナーゼ阻害剤を含む医薬組成物、当該医薬組成物の調製方法及び使用
AU2019382504A1 (en) Cyclic ureas
EP3675860B1 (en) Substituted pyrimidines, pharmaceutical compositions and therapeutic methods thereof
WO2020215998A1 (zh) 嘧啶并五元杂环类化合物及其作为突变型idh2抑制剂的用途
US20210101899A1 (en) Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof
CN117003754B (zh) 吡咯并[2,3-d]嘧啶或吡唑并[3,4-d]嘧啶衍生物及其用途
JP2020530443A (ja) 突然変異体イソクエン酸デヒドロゲナーゼの阻害剤、及びその組成物、並びに方法
EP3720859A1 (en) Positive allosteric modulators of the muscarinic acetylcholine receptor m4
BR122024013896A2 (pt) Compostos de benzamidas derivados de pirazolil-amino-pirimidinila e seus usos, composição farmacêutica dos mesmos, e forma de dosagem unitária compreendendo a mesma
EA048017B1 (ru) Бензамиды производных пиразолил-амино-пиримидинила, композиции на их основе и способы применения
BR122024013977A2 (pt) Compostos de benzamidas derivados de pirazolil-amino-pirimidinila e seus usos, composição farmacêutica dos mesmos, e forma de dosagem unitária compreendendo a mesma
WO2020247679A1 (en) Wdr5 inhibitors and modulators

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: TO AMEND THE APPLICANT NAME TO ISOCURE BIOSCIENCES INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired